Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504963 | 0.83 | DYRK1A (0.39) | RXRARXRBRXRGUSP30DYRK1A | |
| SCHEMBL20233416 | 0.83 | RXRA (0.38) | RXRARXRBRXRGDYRK1AGSK3B | |
| SCHEMBL14785558 | 0.78 | DYRK1A (0.40) | RXRARXRBRXRGDYRK1AGSK3B | |
| SCHEMBL15302571 | 0.77 | CLK2 (0.48) | RXRARXRBRXRGDYRK1A | |
| SCHEMBL12901507 | 0.77 | GSK3B (0.40) | RXRARXRBRXRGDYRK1AGSK3B | |
| SCHEMBL12010092 | 0.77 | CLK2 (0.45) | DYRK1AGSK3BKCNH2 | |
| SCHEMBL12886311 | 0.77 | MCL1 (0.40) | RXRARXRBRXRGDYRK1AKCNH2 | |
| SCHEMBL6503466 | 0.74 | RXRA (0.38) | RXRARXRBRXRGCD274 | |
| SCHEMBL20592887 | 0.74 | RXRA (0.40) | RXRARXRBRXRGCD274IRAK4 | |
| SCHEMBL23565789 | 0.72 | RIPK2 (0.37) | KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016406-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016406-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180153873-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-07 | — | — | US | disclosed |
| US-9763927-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763927-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170065574-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-03-09 | — | — | US | disclosed |
| US-20170065574-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2017-03-09 | — | — | US | disclosed |
| US-9381192-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381192-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160128991-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-05-12 | — | — | US | disclosed |
| US-8703794-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130296341-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2013-11-07 | — | — | US | disclosed |
| US-20130296341-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2013-11-07 | — | — | US | disclosed |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-8252812-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252812-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2011019651-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296341-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-20180153873-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-20170065574-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-20160128991-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-10016406-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | RXRA 2744/4885RXRB 2537/4885RXRG 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.